# OnCo record paper-checkmate-8hw-lancet-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-checkmate-8hw-lancet-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-checkmate-8hw-lancet-2025" ;
  schema:name "CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab alone in MSI-high metastatic colorectal cancer"@en ;
  schema:description "Dual immunotherapy with nivolumab and ipilimumab delayed progression more than nivolumab alone across all lines of treatment in microsatellite-unstable colorectal cancer, with about seven in ten patients progression-free at three years."@en ;
  schema:url <https://onco.cc/key-papers/paper-checkmate-8hw-lancet-2025/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(24)02848-4>, <https://pubmed.ncbi.nlm.nih.gov/39874977/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(24)02848-4> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "André T, Elez E, Lenz HJ, et al." ;
  onco:cancers <https://onco.cc/cancers/msi-high-colorectal/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:trials <https://onco.cc/trials/checkmate-8hw/> ;
  onco:journals <https://onco.cc/journals/lancet/> .